Prevention of Mucosally Induced Uveitis with a HSP60‐derived Peptide Linked to Cholera Toxin B Subunit

P.A. Phipps,Miles Stanford,Jiabin Sun,Bao‐Guo Xiao,Jan Holmgren,Thomas M. Shinnick,Adam Hasan,Yutaka Mizushima,Thomas Lehner
DOI: https://doi.org/10.1002/immu.200390025
2003-01-01
European Journal of Immunology
Abstract:Oral administration of the uveitogenic peptide (aa 336‐351) derived from human HSP60 induced clinical and histological manifestations of uveitis in 65.8% (48/73) of Lewis rats. Uveitis was significantly decreased to 16.7% (11/66) in parallel experiments with the peptide linked to recombinant cholera toxin B subunit (rCTB), also given by mouth (χ 2 =34.2, p <0.0001). The protective efficacy between tolerized and immunized animals was 74.7%. Adoptive transfer of mesenteric lymph node cells from tolerized rats prevented the development of uveitis. A significantly higher proportion of regulatory CD4 + CD45RC low RT6 + subset of Th2 memory cells were found in the mesenteric lymph nodes ( p <0.005) and spleens ( p ⩽0.05) of tolerized rats without uveitis, as compared with immunized rats and uveitis. In situ hybridization studies of mesenteric lymph nodes and/or the uveal tract showed significant increases in IL‐10 and TGF‐β mRNA but decreases in IFN‐γ and IL‐12 mRNA in tolerized, as compared with immunized animals. Thus, the mechanism of tolerance, preventing the development of uveitis may involve a regulatory subset of memory cells and a shift from Th1 to Th2 and Th3 cytokines. We suggest that mucosally induced uveitis can be prevented by oral administration of the peptide‐rCTB conjugate.
What problem does this paper attempt to address?